NEW YORK, NY / ACCESSWIRE / November 23, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
USB Shareholders Click Here: https://www.zlk.com/pslra-1/u-s-bancorp-class-action-submission-form?prid=34011&wire=1
EIGR Shareholders Click Here: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=34011&wire=1
TSP Shareholders Click Here: https://www.zlk.com/pslra-1/tusimple-class-action-loss-submission-form?prid=34011&wire=1
* ADDITIONAL INFORMATION BELOW *
U.S. Bancorp (NYSE:USB)
USB Lawsuit on behalf of: investors who purchased August 1, 2019 - July 28, 2022
Lead Plaintiff Deadline : December 27, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/u-s-bancorp-class-action-submission-form?prid=34011&wire=1
According to the filed complaint, during the class period, U.S. Bancorp made materially false and/or misleading statements and/or failed to disclose that: (a) U.S. Bank created sales pressure on its employees that led them to open credit cards, lines of credit, and deposit accounts without consumers' knowledge and consent; (b) since at least 2015, U.S. Bank and by extension, U.S. Bancorp, was aware of such unauthorized conduct and that it was violating relevant regulations and laws aimed at protecting its consumers; (c) U.S. Bancorp failed to properly monitor its employees from engaging in such unlawful conduct, detect and stop the misconduct, and identify and remediate harmed consumers; (d) all the foregoing subjected the Company to a foreseeable risk of heightened regulatory scrutiny or investigation; (e) U.S. Bancorp's revenues were in part the product of unlawful conduct and thus unsustainable; and (f) as a result, the Company's public statements were materially false and misleading at all relevant times.
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
EIGR Lawsuit on behalf of: investors who purchased March 10, 2021 - October 4, 2022
Lead Plaintiff Deadline : January 9, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=34011&wire=1
According to the filed complaint, during the class period, Eiger BioPharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) defendants overstated Eiger's clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization ('EUA') for the Company's product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda's regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
TuSimple Holdings Inc. (NASDAQ:TSP)
This lawsuit is on behalf of all persons who: (a) purchased or otherwise acquired TuSimple securities pursuant and/or traceable to documents issued in connection with TuSimple's April 15, 2021 initial public offering ; and/or (b) purchased or otherwise acquired TuSimple securities between April 15, 2021 and October 31, 2022, both dates inclusive.
Lead Plaintiff Deadline : January 9, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tusimple-class-action-loss-submission-form?prid=34011&wire=1
According to the filed complaint, (1) TuSimple was engaged in undisclosed related party transactions with Hydron, a company founded by TuSimple's co-founder, Mo Chen; (2) TuSimple shared confidential information and/or proprietary technology with Hydron without the approval of TuSimple's board of directors or informing regulators or TuSimple shareholders; (3) TuSimple failed to disclose the internal investigation by its board of directors into the Company's ties to Hydron, which commenced in July 2022; (4) the aforementioned conduct enhanced the likelihood of regulatory scrutiny and investigatory action toward the Company; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: